Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07453602) titled 'Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234' on March 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Arcutis Biotherapeutics, Inc.
Condition:
Atopic Dermatitis (AD)
Eczema
Intervention:
Biological: ARQ-234
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: March 2, 2026
Target Sample Size: 125
Countries of Recruitment:
United States
To know more, visit https://...